On an uptrend near the 210-day MA (30 weeks) (Wall around €5). Key takeaways:
- Clinical advances on lanifibranor
- Financing and partnerships (including rumors from US pharmaceutical giants)
- Cash flow increasing until mid-2026.
Analysts' speculative price target around €8. Everything will depend on the feedback from lanifibranor's advances. The Chinese paid $10 million as part of a partnership. I have a PRU of €2.93. I'm sticking with this company for the long term.
- Clinical advances on lanifibranor
- Financing and partnerships (including rumors from US pharmaceutical giants)
- Cash flow increasing until mid-2026.
Analysts' speculative price target around €8. Everything will depend on the feedback from lanifibranor's advances. The Chinese paid $10 million as part of a partnership. I have a PRU of €2.93. I'm sticking with this company for the long term.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。